TNF and rheumatoid arthritis: The recent introduction of biosimilar infliximab (marketed as Inflectra® and Remsima®), an anti-TNF biologic indicated for RA, AS, CD, and UC among other conditions, to the EU markets, may address this issue of increasing financial impact of treatment with biologics.